1986
DOI: 10.1111/j.1365-2222.1986.tb01983.x
|View full text |Cite
|
Sign up to set email alerts
|

Low dose sublingual therapy in patients with allergic rhinitis due to house dust mite

Abstract: Summary In a double‐blind placebo‐controlled cross‐over trial, low dose sublingual therapy with house dust mite was effective in relieving symptoms in 72% of the group of patients with perennial rhinitis due to house dust mite (P < 0·03). Following active treatment, there was a significant increase in morning peak nasal inspiratory flow rate (P < 0·01) in those who improved (thirteen out of eighteen) and resistance to nasal provocation with house dust mite also increased, in some cases up to 1000‐fold (P < 0·0… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

1
113
0
8

Year Published

1988
1988
2018
2018

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 247 publications
(122 citation statements)
references
References 28 publications
1
113
0
8
Order By: Relevance
“…To reduce side effects in the course of SIT, both Marsh et al and Lee and Sehon developed procedures for the chemical modification of allergen extracts and obtained modified allergen extracts with low allergenic activity [22,23]. In 1986, Scadding and Brostoff [24] Table 1 Overview of milestones in the development of SIT 1903 Pollen-specific anti-sera neutralize pollen-induced allergic reactions Dunbar [15] 1911 Subcutaneous injection of grass-pollen extract in allergic patients reduces allergic symptoms Noon [16] 1927 Oral administration of pollen extract for SIT Black [17] 1935 Demonstration that SIT induces an allergen-specific serum factor that inhibits allergic reactions…”
Section: Milestones In the Development Of Sitmentioning
confidence: 99%
“…To reduce side effects in the course of SIT, both Marsh et al and Lee and Sehon developed procedures for the chemical modification of allergen extracts and obtained modified allergen extracts with low allergenic activity [22,23]. In 1986, Scadding and Brostoff [24] Table 1 Overview of milestones in the development of SIT 1903 Pollen-specific anti-sera neutralize pollen-induced allergic reactions Dunbar [15] 1911 Subcutaneous injection of grass-pollen extract in allergic patients reduces allergic symptoms Noon [16] 1927 Oral administration of pollen extract for SIT Black [17] 1935 Demonstration that SIT induces an allergen-specific serum factor that inhibits allergic reactions…”
Section: Milestones In the Development Of Sitmentioning
confidence: 99%
“…However, if the reactions are of the anaphylactic type, they may be severe and, though very rarely, even fatal [7]. In 1987, the sublingual route was proposed for AIT [8], and in the ensuing years it emerged as the best option for immunotherapy, by demonstrating a comparable efficacy and better Riassunto (Il trattamento della rinite allergica con l'immunoterapia sublinguale: revisione della letteratura). Obiettivo.…”
Section: Introductionmentioning
confidence: 99%
“…AR is a chronic disease showing symptoms of nasal congestion, nasal itching, rhinorrhea and sneezing [2]Medical cost for AR treatment is increasing, and considering comorbid diseases including asthma, the treatment of AR has become more than just treating the rhinitis itself [3]. AR treatment can be classified into 4 categories: (1) avoidance and environmental control, (2) pharmacotherapy, (3) surgical treatment and (4) immunotherapy.…”
Section: Introductionmentioning
confidence: 99%
“…AR treatment can be classified into 4 categories: (1) avoidance and environmental control, (2) pharmacotherapy, (3) surgical treatment and (4) immunotherapy. Avoidance and environmental control is the safest way, but these are not always feasible.…”
Section: Introductionmentioning
confidence: 99%